A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers

By Toledo H.   Baly A.   Castro O.   Resik S.   Laferte J.   Rolo F.   Navea L.   Lobaina L.   Cruz O.   Mguez J.   Serrano T.   Sierra B.   Perez L.   Ricardo M.E.   Dubed M.   Lubian A.L.   Blanco M.   Millan J.C.   Ortega A.   Iglesias E.   Penton E.   Martn Z.   Perez J.   Daz M.   Duarte C.A.  

Vaccine, Vol. 19, Iss. 30, 2001-07 ,pp. : 4328-4336

Elsevier

Access to resources Recommend Favorite

Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant

By Saul A.   Lawrence G.   Smillie A.   Rzepczyk C.M.   Reed C.   Taylor D.   Anderson K.   Stowers A.   Kemp R.   Allworth A.   Anders R.F.   Brown G.V.   Pye D.   Schoofs P.   Irving D.O.   Dyer S.L.   Woodrow G.C.   Briggs W.R.S.   Reber R.   Sturchler D.  

Vaccine, Vol. 17, Iss. 23, 1999-08 ,pp. : 3145-3159

Elsevier

Access to resources Recommend Favorite

The V3 loop based multi-epitope polypeptide TAB9 adjuvated with montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against five HIV-1 isolates

By Gomez C.E.   Navea L.   Lobaina L.   Dubed M.   Exposito N.   Soto A.   Duarte C.A.  

Vaccine, Vol. 17, Iss. 18, 1999-05 ,pp. : 2311-2319

Elsevier

Access to resources Recommend Favorite

A prime-boost regime that combines Montanide ISA720 and Alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9

By Exposito Raya N.   Quintana D.   Carrazana Y.   Gomez C.E.   Duarte C.A.  

Vaccine, Vol. 17, Iss. 20, 1999-06 ,pp. : 2646-2650

Elsevier

Access to resources Recommend Favorite

International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants

By Barnett P.V.   Pullen L.   Williams L.   Doel T.R.  

Vaccine, Vol. 14, Iss. 13, 1996-09 ,pp. : 1187-1198

Elsevier

Access to resources Recommend Favorite